Skip to main content
. Author manuscript; available in PMC: 2009 Dec 15.
Published in final edited form as: J Immunol. 2008 Dec 15;181(12):8753–8760. doi: 10.4049/jimmunol.181.12.8753

Figure 6.

Figure 6

Prevention of SAP by a single intravenous injection of P0 (180–199), but not by injection of PBS or other peptides in B7-2 KO NOD mice at 2 or 4 mo. A. Clinical scores. Three groups of animals were compared [n = 9 for P0 (180–199); n = 10 for PBS; other peptides include P2 (53–78), OVA (323–339), n = 3 each; p <0.0001 for P0 (180–199) vs PBS or other peptides at 8 mo]. Peptide dose injected: 200 µg. B. Incidence of neuropathy in these 3 groups of mice. C. Grip strength measurements (* At 8 mo, p < 0.0006 for P0 (180–199) vs PBS and other peptides in forelimb and p <0.0001 in hindlimb grip strength). D. Sciatic nerve electrophysiology at 8 mo. Distal latencies (DL), conduction velocities (CV) and amplitudes (AMP) of sciatic motor responses were measured. * DL: p < 0.009 for P0 (180–199) vs PBS or other peptides; CV: p< 0.003; Amp: p < 0.001.